AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02914886
Drug: Apidra
RxNorm normalized name: Apidra
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
Trial: NCT02914886
Drug: current insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
Trial: NCT00001784
Drug: Mexiletine
RxNorm normalized name: Mexiletine
DrugBank: Mexiletine (DB00379)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03579719
Drug: Balovaptan
RxNorm normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20.
Trial: NCT03579719
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
Trial: NCT01929603
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
Trial: NCT01929603
Drug: Olaparib tablet dosing
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
Trial: NCT01787747
Drug: AVP-786 Dose 1
RxNorm normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01787747
Drug: AVP-786 Dose 2
RxNorm normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01787747
Drug: AVP-923
RxNorm normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02034565
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00517114
Drug: Rabeprazole 20mg twice daily
RxNorm normalized name: rabeprazole sodium 20 MG
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00778401
Drug: Gabapentin tablets 800 mg
RxNorm normalized name: gabapentin Oral Tablet
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02262663
Drug: Vilaprisan (BAY1002670)
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04597801
Drug: Alcon
RxNorm normalized name: alconox
DrugBank: Sofalcone (DB05197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorescein sodium is administered intravenously with a bolus injection of 5 mg per kg of bodyweight 20-40 minutes prior to the planned tumor resection.
Trial: NCT02474498
Drug: EMD
RxNorm normalized name: Zemdri
DrugBank: Plazomicin (DB12615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
Trial: NCT00000222
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01833078
Drug: ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ghrelin administration subcutaneously for 7 days
Trial: NCT00742157
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
Trial: NCT05807945
Drug: Ropivacaine 0.75% Injectable Solution
RxNorm normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.75%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
Trial: NCT05807945
Drug: Ropivacaine 0.2% Injectable Solution
RxNorm normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
Trial: NCT02957019
Drug: L19-IL2 - Ph I
RxNorm normalized name: L19-IL2
DrugBank: Darleukin (DB17157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
Trial: NCT02957019
Drug: L19-IL2 at RD - Ph II
RxNorm normalized name: L19-IL2
DrugBank: Darleukin (DB17157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
Trial: NCT02957019
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
Trial: NCT01686321
Drug: Bendamustine and subcutaneous rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04426357
Drug: JNJ-64417184
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
Trial: NCT04053023
Drug: GSK2330672 (linerixibat)
RxNorm normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330672 is available as a tablet with unit dose strength of 45 mg.
Trial: NCT00437073
Drug: topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
Trial: NCT00437073
Drug: lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: lapatinib administered 1250mg once daily orally
Trial: NCT03464201
Drug: Enzalutamide 40 MG
RxNorm normalized name: enzalutamide 40 MG
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg p.o. every day
Trial: NCT00860496
Drug: CP- 690,550 and Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
Trial: NCT00860496
Drug: CP- 690,550 and Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
Trial: NCT04053023
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
Trial: NCT02810392
Drug: Intranasal Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.
Trial: NCT02215473
Drug: Chlorhexidine gluconate mouth rinse
RxNorm normalized name: chlorhexidine gluconate Mouthwash [Denti-Rinse]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
Trial: NCT00811850
Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
Trial: NCT00811850
Drug: fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
RxNorm normalized name: dorzolamide / timolol Ophthalmic Solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
Trial: NCT00353912
Drug: valsartan + amlodipine
RxNorm normalized name: amlodipine / valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02941445
Drug: sitagliptin and metformin
RxNorm normalized name: Sitagliptin and Metformin Hydrochloride Extended Release Tablets
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02941445
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00362115
Drug: Azilsartan Medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Trial: NCT00362115
Drug: Azilsartan Medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Trial: NCT00362115
Drug: Azilsartan Medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Trial: NCT00362115
Drug: Azilsartan Medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Trial: NCT00362115
Drug: Azilsartan Medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Trial: NCT00362115
Drug: Olmesartan
RxNorm normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Trial: NCT01980355
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04665895
Drug: Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: twice daily inhalation throughout the study
Trial: NCT03682484
Drug: MA-0211
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02793050
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Collection of data on the clinical use of Trabectedin
Trial: NCT04600089
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline infusion
Trial: NCT04600089
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
Trial: NCT00553969
Drug: carvedilol phosphate
RxNorm normalized name: carvedilol phosphate
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
Trial: NCT00553969
Drug: lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
Trial: NCT00553969
Drug: carvedilol phosphate and lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
Trial: NCT00622206
Drug: ritonavir and saquinavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
Trial: NCT00835354
Drug: Cefprozil for oral suspension 250 mg/5 mL
RxNorm normalized name: cefprozil Oral Suspension
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 250 mg/5 mL, single-dose fasting
Trial: NCT01653314
Drug: Megavec
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01653314
Drug: Glivec
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03510715
Drug: Alirocumab SAR236553 (REGN727)
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)
Trial: NCT03510715
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Trial: NCT03510715
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: tablet,~Route of administration: oral
Trial: NCT03510715
Drug: Cholestyramine
RxNorm normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: oral suspension,~Route of administration: oral
Trial: NCT03510715
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Trial: NCT03510715
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Trial: NCT03510715
Drug: Omega-3 fatty acids
RxNorm normalized name: Omega-3 Fatty Acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule,~Route of administration: oral
Trial: NCT00713193
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-3 mg/kg orally in a twice day divided dose for 6 months
Trial: NCT00713193
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
Trial: NCT06080204
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。
Trial: NCT02990702
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03181984
Drug: Hemoporfin
RxNorm normalized name: Hemoporfin
DrugBank: Hemoporfin (DB16183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoporfin mediated photodynamic therapy
Trial: NCT01303796
Drug: Sapacitabine
RxNorm normalized name: Sapacitabine
DrugBank: Sapacitabine (DB06365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sapacitabine capsules
Trial: NCT00697385
Drug: Cyclokapron
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (2) 500mg tablets taken by mouth every 6-8 hours
Trial: NCT02457793
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
Trial: NCT02457793
Drug: GDC-0994
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
Trial: NCT02401594
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
Trial: NCT02401594
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
Trial: NCT01622972
Drug: Polyethyleneglycol
RxNorm normalized name: 2-(4-(4-((1-(107- (4-(fluorophenyl)methoxy)-polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5- diiodophenoxy)-3,5-diiodophenyl)acetic acid
DrugBank: 2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400 (DB03556)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
Trial: NCT01303796
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine intravenous
Trial: NCT02757768
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
Trial: NCT02757768
Drug: Tamsulosin Hydrochloride
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
Trial: NCT01128595
Drug: Fluticasone Furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01532648
Drug: Budesonide MMX®
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablet taken daily in the morning after breakfast.
Trial: NCT01532648
Drug: 5-ASA
RxNorm normalized name: 5-ASA
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acceptable oral 5-ASA medications to be received during the study include:~* Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~* Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~* Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~* Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g
Trial: NCT01857232
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5HT3-antagonist
Trial: NCT01857232
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Corticosteroid
Trial: NCT01857232
Drug: Fosaprepitant
RxNorm normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NK1 antagonist
Trial: NCT03968042
Drug: Nerve Growth Factor
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection for 2 weeks
Trial: NCT03968042
Drug: Edaravone
RxNorm normalized name: Edaravone
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous injection for 2 weeks
Trial: NCT03968042
Drug: Combination of vitamin B1, B6, C, E and mecobalamine
DrugBank: Mecobalamin (DB03614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
Trial: NCT00775671
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg by mouth daily for 12 weeks.